

**5 December 2022**

## **ASX Announcement**

### **ISLA-101 trial update and investor presentation**

MELBOURNE Australia, 5 December 2022: Australian mid-clinical stage antiviral drug development company, Island Pharmaceuticals Ltd (ASX: ILA; “Island”; “the Company”) is pleased to provide a brief progress update on its ISLA-101 Phase 2a PEACH<sup>1</sup> human clinical trial, and to share a copy of the presentation being delivered to investors in meetings through December 2022.

Following the recent news (ASX announcements: 14 November 2022 and 28 October 2022) that clinical drug product had been manufactured for the Company's ISLA-101 Phase II clinical trial in dengue fever, Island has now made its Institutional Review Board submission, which is analogous to an application for Human Research Ethics Committee (HREC) approval. This is an important regulatory requirement ahead of trial commencement.

CEO of Island Pharmaceuticals, Dr David Foster said, *“We are excited by the pace with which our trial preparation is now moving and look forward to keeping the market updated as we make further progress in the coming weeks.”*

*Investors can expect updates on the final results of our clinical drug product stability and ethics committee submission. We are also in the final stages of preparing our Investigational New Drug application for submission to the US FDA.”*

A copy of the presentation being delivered to investors through meetings in December 2022 is attached.

#### **Approved for release to the ASX by:**

Dr Paul MacLeman  
Executive Chairman  
Island Pharmaceuticals Ltd  
[info@islandpharmaceuticals.com](mailto:info@islandpharmaceuticals.com)

Investors and media, for further information, please contact:

Jane Lowe  
IR Department  
Mobile: +61 411 117 774  
[jane.lowe@irdepartment.com.au](mailto:jane.lowe@irdepartment.com.au)

---

<sup>1</sup> The PEACH study is a Phase 2a Randomized, Double Blind, Placebo-controlled Study for the Prophylactic Examination of an Antiviral in a Dengue Challenge model.



## About Island Pharmaceuticals

---

Island (ASX: ILA) is a mid-clinical-stage drug repurposing company, focused on the topical area of antiviral therapeutics for infectious diseases. Our lead asset is ISLA-101, a drug with a well-established safety profile, being repurposed for the prevention and treatment of dengue<sup>2</sup> fever and other mosquito (or vector) borne diseases. The Company is close to commencing a Phase 2a clinical trial in dengue-infected subjects.

If ISLA-101 achieves FDA approval, and certain other criteria are met, Island may be eligible to obtain a "Priority Review Voucher" at the time of FDA approval. This means that as well as getting approval to manufacture and sell ISLA-101, the Priority Review Voucher (PRV) could permit Island to expedite the FDA approval process for a new drug or sell the PRV in a secondary market.

*Island encourages all current investors to go paperless by registering their details with the Company's share registry, Automic Registry Services, whose contact info is housed on the Shareholder Services page of the Company's website.*

Visit [www.islandpharmaceuticals.com](http://www.islandpharmaceuticals.com) for more on Island.